EVE EVE Health Group Limited
Consumer Defensive · Packaged Foods
· website
$0.02
52wk 0.01 – 0.04
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About EVE Health Group Limited
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$5.64M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.47
EV / EBITDA
-2.22
Price / Book
1.23
ROE
-77.7%
Operating margin
-134.5%
Net margin
-119.1%
Total cash
$929,659
Total debt
$38,514
Current ratio
3.48
Debt / Equity
0.01
Free cash flow
$-715,692
Avg volume
340,970
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$1.73M
- Gross profit$824.03K
- Operating income-$1.43M
- Net income-$1.58M
- Diluted EPS-0.01
- Free cash flow-$1.62M
- Net debt-$812.14K